Camptothecin Ligand-Drug Conjugates for Lower Toxicity Chemotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing camptothecin derivatives, such as exatecan, suffer from high cellular toxicity and a narrow therapeutic window, limiting their effectiveness as standalone chemotherapy agents despite their potent anticancer activity.
Innovation Solution
Development of camptothecin derivatives represented by Formula 1, which are designed with specific substituents and linkers to enhance safety and efficacy, forming ligand-drug conjugates that target cancer cells effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If camptothecin derivatives are used as standalone chemotherapy agents, then potent anticancer activity is achieved, but high cellular toxicity and narrow therapeutic window occur
Solution Approach 1:
The invention divides the drug delivery system into three distinct components: an antibody (ligand) for target recognition, a linker for conjugation, and the camptothecin derivative (drug) for cytotoxic action. This segmentation allows the drug to be delivered specifically to cancer cells while minimizing exposure to healthy cells, thereby reducing cellular toxicity while maintaining anticancer activity.
Solution Approach 2:
The invention introduces an antibody-ligand complex as an intermediary carrier to transport the camptothecin derivative specifically to cancer cells. This intermediary mechanism enables targeted delivery, ensuring the drug reaches its destination efficiently while reducing off-target effects and cellular toxicity in non-cancerous tissues.
2Reliability
If camptothecin derivatives are used as standalone chemotherapy agents, then potent anticancer activity is achieved, but narrow therapeutic window occurs
Solution Approach 1:
By segmenting the drug delivery into target-specific components (antibody, linker, drug), the invention enables selective action against cancer cells. This segmentation expands the therapeutic window by allowing higher drug concentrations at the tumor site without proportionally increasing systemic toxicity, thus improving the ratio between effective dose and toxic dose.
Solution Approach 2:
The invention applies local quality by concentrating the camptothecin derivative's cytotoxic effect specifically at the cancer cell location through antibody-mediated targeting. The drug exhibits high potency locally at the tumor site while maintaining low toxicity systemically, thereby expanding the therapeutic window through spatial differentiation of drug action.
3Reliability
If ligand-drug conjugates are developed with specific substituents and linkers, then safety and efficacy are enhanced, but device complexity increases
Solution Approach 1:
The invention employs a universal linker structure that can conjugate various camptothecin derivatives to different antibody ligands. This multi-functional linker design maintains consistent pharmacokinetic properties and targeting mechanisms across different conjugate variants, enhancing safety and efficacy while managing complexity through standardized modular components.
Solution Approach 2:
The invention systematically varies specific parameters (substituent groups R1-R6 on the camptothecin core, linker length and composition) to optimize safety and efficacy. By controlling and adjusting these parameters within defined ranges, the invention enhances therapeutic performance while maintaining manageable structural complexity through rational molecular design.
Data Source
Figure 1~3
Figure 4~6
Figure 7~9
AI summary
Disclosed in the present invention are a new camptothecin derivative, a linker, a ligand-drug conjugate, and a pharmaceutical composition thereof containing the camptothecin derivative or the conjugate, and the corresponding medical use.